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ABSTRACT OF THESIS 
 
 
 
 
MICROSPHERE SPRAY SYSTEM FOR WOUND COVERAGE 
 
 
 Spinal fusion is used to treat diseases or disorders of the spine by fusing together 
two or more vertebrae. Two associated risks with spinal fusion are infection and blood 
loss. Administration of tranexamic acid is used to prevent blood loss, and transfusions are 
given following blood loss. Surgical site infections are prevented with vancomycin 
powder spread into the surgical wound, while established infections are treated by 
debridement and delivery of antibiotics for 4 to 6 weeks. The present research explored 
an alternate method to prevent and treat blood loss or infection in spinal fusion. 
Poly(lactic-co-glycolic acid) (PLGA) microspheres was used to encapsulate vancomycin 
for 42 days to treat infection. Vancomycin encapsulated in gelatin microspheres had a 
controlled release of 7 days to prevent infection. Tranexamic acid was dissolved into 
phosphate-buffered saline or carboxymethylcellulose to provide a release of 6 hours to 
prevent blood loss after surgery. The microspheres and tranexamic acid were delivered to 
a target region using a water based spray system. The spray system demonstrated the 
delivery and distribution of drugs to a target region. The microsphere spray system is 
capable of spraying drugs onto a target region to prevent or treat blood loss and infection 
over time.   
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 INTRODUCTION 
 
Spinal fusion is a type of surgery that involves permanently fusing together two or more 
vertebrae in the spine to stop motion between them. Spinal fusion surgery is often needed 
to correct conditions from degenerative disc disease, scoliosis, spondylosis, vertebrae 
fracture and several other degenerative spinal conditions. The surgery frequently requires 
instrumentation to fix the condition by stabilizing and aligning the spine.  
 
Two major risks of spinal fusion are major blood loss and a postoperative infection. A 
patient can lose up two liters of blood during and after surgery, which can result in a 
variety of issues. A postoperative infection in the surgical site results in extended hospital 
stays, increased patient cost, and other health risks.  
 
Blood loss is treated by having the patient receive blood transfusions. Blood transfusions 
have associated risks with them such as infection, transmission of blood borne diseases, 
allergic reaction and delayed hemolytic reaction.  
 
Surgical site infections are treated by administering antibiotics intravenously for an 
average of 6 weeks, followed by oral antibiotics for several months. To prevent surgical 
site infections, antibiotics in powder form can be spread into the surgical site. The current 
method to prevent infections requires intravenous antibiotics daily and requires a large 
dose of antibiotics spread into the wound. A large amount of antibiotics are lost due to 
wound drainage. The patient must remain in the hospital for an extended time due to the 
need for intravenous antibiotics. This increase in hospital care can be a financial burden. 
There is no current method that has sustained or controlled release of antibiotics which 
would allow the patient to return home.  
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This research focused on spinal fusion surgery and the various issues with the current 
prevention/ treatment options by using biomaterials engineering. Poly(lactic-co-glycolic 
acid) (PLGA) and gelatin were used as the polymers to deliver antibiotics over extended 
time to the surgical site. PLGA and gelatin are both biodegradable and nontoxic. PLGA 
and gelatin were both formed into microspheres to encapsulate vancomycin. Tranexamic 
acid was suspended in solution to be locally delivered to the surgical site. A water based 
spray system was utilized to spray either PLGA or gelatin microspheres in a tranexamic 
acid solution directly onto the surgical site. This would allow for the simultaneous 
delivery and sustained release of tranexamic acid and/or vancomycin. Therefore, it would 
treat or prevent blood loss and infection at the same time.  
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 BACKGROUND AND SIGNIFICANCE 
2.1. Spinal fusion 
 
Spinal fusion surgeries have been occurring since the early 1900s to treat various diseases 
or conditions of the spine. Spinal fusion is used to treat deformity, trauma, degenerative 
disc disease, scoliosis and spondylolisthesis [1]. The surgery is the permanent fixation of 
two or more vertebrae and often requires the use of instrumentation to stabilize the spine 
[2]. There are three different sections to the spine that can require fusion; the cervical, 
thoracic and lumbar curve. From 1998 to 2008 there has been a 114% increase in cervical 
fusion, an 82% increase in  thoracic fusion and 171% increase in lumbar fusion in the 
United States [1]. It is clear there is an increasing number of spinal fusion required each 
year, but spinal fusion has associated risks in blood loss and infection.  
2.2. Spinal fusion blood loss 
 
A patient can lose up to 2 liters of blood during surgery and up to a liter of blood can be 
lost postoperatively [3]. To replace the blood lost, a patient will have blood transfusions. 
The amount of blood lost is directly related to the number of vertebrae fused. For 2-3 
vertebrae fused, a patient will have 8.3% of their overall blood transfused. For 4-8 
vertebrae fused 18.5% of their overall blood is transfused and ≥9 vertebrae fused 37.9% 
overall of the patient’s blood is transfused [4]. In adult spinal fusion, the percentage of 
transfusions required in patients ranges between 50% and 81% [5]. Blood transfusions 
have serious risks such as reactions to transfused blood, alloimmunization, transfusion-
associated bacterial sepsis and infection risks which include human immunodeficiency 
virus and hepatitis [3, 5, 6]. 
 
2.3. Spinal fusion surgical site infections 
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Another serious risk of surgery is a surgical site infection (SSI), especially in spinal 
fusion involving instrumentation. The incidence of infection in spinal fusion surgery 
involving instrumentation ranges from 2.1% to 8.5% [7]. There are over 500,000 SSIs in 
America each year which results in an expenditure of billions of dollars [8]. In America 
there were approximately 415,000 spinal fusion surgeries in 2008. If the incident rate of 
infection is 8.5% that would result in 35,275 SSIs each year [1]. The mean cost per 
infection is approximately $34,000 and the infection related cost per 100 spinal fusions is 
approximately $438,000 [8]. Therefore, the total infection related cost of SSIs in spinal 
fusion is approximately $154 million dollars per year in the United States. The most 
predominate organism to cause SSIs is Staphylococcus aureus. S.aureus was found in 
73% of deep SSIs cases and 86% in superficial SSIs [2, 7, 9]. Starting on October 1, 2008 
a new Medicare policy was put into place for preventable conditions such as infections. 
The policy was a reduced payment for these conditions. Therefore, Medicare no longer 
paid hospitals more for a patient who developed a preventable condition after admission. 
This meant hospitals and insurance companies would not be covering the cost of a 
surgical site infections [10, 11]. The patient can no longer expect reimbursement for an 
infection developed after spinal fusion.  
 
2.4. Treatment and prevention of blood loss 
 
Due to the significant amount of blood loss in spinal fusions there are treatment and 
preventative methods which are currently being used. To treat blood loss from surgery, a 
patient will need to have blood transfusions to replace the blood lost [3]. The technique to 
prevent or reduce blood lost during surgery is the use of tranexamic acid. Tranexamic 
acid can be administered several different ways. Typically, 1 gram of tranexamic acid is 
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administered intravenously for an hour before surgery and then 1 gram of tranexamic 
acid for 6 to 12 hours after surgery, depending on the amount of blood loss [12]. It has 
been shown that the use of tranexamic acid before and after surgery reduced 
intraoperative blood loss by 126 ml, postoperative blood loss by 215 ml and total blood 
loss by 408 ml. In each case the blood loss was reduced by less than or equal to 50% 
[13]. The use of tranexamic acid additionally reduced the need for a blood transfusion by 
49% [6, 14]. Tranexamic acid has been shown to be administered topically in total hip 
and knee arthroplasty. Patients received 2 grams of tranexamic acid in 100 ml of normal 
saline which was then used to bathe the surgical site. The study showed that tranexamic 
acid had 119 ml of blood transfused compared to a saline bath which had 198 ml of blood 
transfused [15, 16]. The use of topical tranexamic acid reduced the amount of transfusion 
required which means the overall blood loss was reduced. 
 
2.5. Treatment and prevention of infection 
 
Due to the serious nature of a surgical site infection there are several ways to prevent an 
infection. The most common methods to prevent a SSI after spinal surgery are antibiotic 
prophylaxis and the use of vancomycin powder in the surgical site after surgery and 
before the closing of the surgical site [7]. To prevent an infection, 1 to 2 grams of 
vancomycin powder is spread into the surgical wound, and in rare cases, up to 6 grams of 
vancomycin powder can be used [17]. The use of vancomycin powder has been shown to 
bring infection rates down from 8.5% to 0% [18-21]. When vancomycin powder is used 
in the surgical wound, significant levels of vancomycin can be measured in the surgical 
drain. On the day of the surgery, up to 1457 µg/ml can be found in the drain. The day 
after surgery, 462 µg/ml is found and on the 2nd after surgery 270 µg/ml can be found 
 
 
6 
 
[22]. Most of the vancomycin is being flushed out of the wound and isn’t being used to 
prevent the infection. The current method to prevent infection is very inefficient, wastes 
antibiotics and exposes the patient to high levels of antibiotics. If the infection is not 
prevented the wound site must be treated to eradicate the infection. The first way to treat 
an infection is aggressive surgical treatment such as debridement. Debridement treats the 
infection by surgically removing the dead tissues and the instrumentation used in the 
surgery [7, 23]. The surgical site is then irrigated with antibiotics until the infection is 
eradicated and then another surgery is needed to replace the instrumentation. In spinal 
fusion surgery, the instrumentation cannot be removed without a risky surgery and 
possibly progressing the spinal deformity being treated. The instrumentation is needed in 
spinal fusion to preserve the spines stability [2].  The second step to treat a SSI after 
spinal fusion is a course of antibiotics such as vancomycin. After an infection is found in 
the surgical site antibiotics are given intravenously for a mean time of 6 weeks [24, 25]. 
After the six weeks of intravenous antibiotics the patient will often undergo a course of 
oral antibiotics for mean time of 3 to 6 months until the infection is eradicated [2, 26]. 
 
2.6. Vancomycin and tranexamic acid used 
 
Vancomycin is a glycopeptide antibiotic that was first discovered from a soil sample in 
Borneo in 1956 by a soil screening program at Eli Lilly [27].Vancomycin inhibits cell 
wall synthesis  by binding to the D-Ala-D-Ala terminus of peptidoglycan pentapeptide, 
which as a result, inhibits transglycosylase, preventing peptidoglycan elongation and 
cross-linking against Gram-positive organisms such as S. aureus [27, 28]. Vancomycin 
has a molecular mass of 1449 g/mol. It is typically thought of a last resort drug [29]. 
Some side effects of vancomycin are redness, swelling and hyperpigmentation. 
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Vancomycin is not effective when administered orally. It must be administered 
intravenously or directly into the wound [29].  
 
Tranexamic acid is a synthetic derivative of lysine and is an antifibrinolytic agent that 
reduces blood loss. Tranexamic acid reduces blood loss by inhibiting the binding of fibrin 
to plasmin which stops the activation of plasminogen. Plasmin is responsible for breaking 
down fibrin clots [30]. By inhibiting the activation of plasminogen to plasmin, clots 
cannot be broken down and blood loss is reduced [14]. The molecular mass of tranexamic 
acid is 157.21 g/mol. Tranexamic acid is generally administered intravenously or in a 
solution [6].  
 
2.7. Poly(lactic-co-glycolic acid) 
 
Poly(lactic-co-glycolic acid) (PLGA) is a copolymer consisting of the monomers lactic 
and glycolic acid. PLGA is a Food and Drug Administration (FDA) approved polymer 
for drug delivery use in humans. PLGA is widely used due to its biocompatibility and 
tailored biodegradation rate [31]. PLGA can act as a carrier for various drugs such as 
peptides, proteins and antibiotics. PLGA releases its drug through a network of pores.  
PLGA undergoes hydrolytic degradation by the cleavage of its ester linkages which are 
present in the backbone of PLGA. Upon degradation, the byproducts of PLGA are 
nontoxic and are naturally produced through normal metabolic pathways. These 
metabolic pathways are used to eliminate PLGAs byproducts [31]. There are many 
different properties that affect the degradation rate of PLGA. Some of these include 
crystallinity of the polymer, polymer chemistry (acid end group or aliphatic end group) 
and ratio of lactic to glycolic acid [31].   PLGA with an acid end group will degrade 2-4 
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fold faster depending whether it is in vivo or in vitro. The acid terminated PLGA 
degrades quicker due to its faster uptake of water [32]. An application of PLGA is the 
formation of microspheres for controllable drug delivery.  It was shown using 70:30 
PLGA and 90:10 PLGA to deliver vancomycin to the brain. The PLGA microspheres 
were created using a double emulsion and they were able to achieve a release of 63 days 
[33].  Antibiotic coated implants are a growing field in research. Implants can be coated 
with a thin film or layer of antibiotics to prevent or treat infection in surgical wounds [34, 
35]. Other antibiotic delivery systems can include particle injections, bone cements, skin 
patches and antibiotic coatings on implants. 
 
2.8. Gelatin   
 
Gelatin is derived from natural proteins which can be derived from the skin of pigs, cattle 
bones and in rare instances, fish scales. Gelatin is denatured collagen which consists 
mainly of three amino acids glycine, proline and hydroxyproline [36]. Gelatin is 
biocompatible, biodegradable, non-immunogenic and a FDA approved polymer for 
human consumption. Gelatin is also approved by the FDA for use in some surgical 
products, one product is a gelatin sterile sponge which is used to prevent blood loss [37]. 
This makes it a very useful polymer for drug delivery and controlled release. Gelatin has 
a history of being used for tissue engineering scaffolds, hydrogels, microspheres and drug 
delivery matrices [38]. Gelatin is insoluble at room temperature, but soluble at body 
temperature. Gelatin can be crosslinked by various compounds. One of these compounds 
is glutaraldehyde which used to form new bonds and slow down the degradation rate 
through crosslinking. Schiff base linkages are formed in the gelatin, this occurs through 
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the formation of imines between ε- amino groups from the gelatin and the glutaraldehyde 
[39, 40]. 
 
2.9. Carboxymethylcellulose 
 
Carboxymethylcellulose (CMC) is a derivative of cellulose which, is a polysaccharide 
that is naturally water soluble [41]. CMC is derived from cellulose through an alkali-
catalyzed reaction. CMC differs from cellulose because it is soluble and chemically 
active. CMC is a FDA approved food additive and is in many nonfood products such as 
toothpastes and detergents. CMC is mainly used in the food industry as a viscosity 
modifier or thickener [42]. CMC is additionally approved for use in various surgical 
products, one product is an adhesion barrier which prevents undesired contact between 
tissues [43]. In current research CMC is being used in many various different ways, a few 
ways CMC is being used are to create CMC microparticles for microfluidics and as a 
viscous solution for the injection of gelatin particles [44, 45]. 
 
2.10. Spray systems 
 
Topical antimicrobials have been in use since the dawn of civilization. Some examples of 
these include various molds and plant extracts to treat burns or infections [46]. It wasn’t 
until after World War I in 1925 that the first spray system was designed. The topical 
spray system was first used at Henry Ford Hospital to treat burn wounds. The spray 
system used a 2.5% tannic acid aqueous solution as the fluid medium. This aqueous 
solution was directly sprayed onto the burn wound [47]. The designer, Davidson, 
hypothesized that the spray system would reduce pain and keep the wound site cleaner 
due to the removal of physically interaction with the wound to apply drugs [48]. Topical 
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sprays allow the antibiotics or antimicrobials to be delivered to a wound site without 
physically touching the wound. There are many different sprays system in use today that 
are administered orally or nasally such as Zicam, Nasacort and Albuterol. 
 
2.11. Significance  
 
The goal of this project was to improve the outcomes of spinal surgery today. By 
combining tranexamic acid and vancomycin into a single delivery spray system, two 
different treatments can be performed simultaneously. This will help reduce blood loss 
and infections in the surgical wound, which will reduce patient costs and many other 
issues. The overall goal was to further improve success of procedures by developing 
spray system to uniformly deliver agents for reducing blood loss and preventing or 
treating infection. This was achieved with the short term delivery of tranexamic acid, the 
intermediate and longer-term release of vancomycin.  
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 METHODS AND MATERIALS 
 
3.1. Poly(lactic-co-glycolic acid) microspheres 
 
PLGA microspheres were prepared using a double-emulsion process (W1/O/W2) [49]. 
Vancomycin (GOLDBIO; St. Louis, MO) was loaded into phosphate-buffered saline 
(PBS) with a pH of 7.4 at 150 mg/ml as the W1 phase. Tranexamic acid (Acros Organics; 
Bridgewater, New Jersey) was loaded into PBS at 150 mg/ml or 75 mg/ml as the W1 
phase.  One g of PLGA (75:25 L:G, ester-terminated, inherent viscosity 0.55-0.75 dL/g; 
Durect; Cupertino, California) was dissolved in 15 mL of dichloromethane (DCM) as the 
oil phase. The W2 phase consisted of 1.75 g of methylcellulose and 25 g NaCl dissolved 
in diH2O. The W1 phase (1 mL) was added to the oil phase and sonicated three times for 
20 seconds each to prevent excessive heating. 300 mL of the W2 phase was homogenized 
at 4000 rotations per minute (RPMs) for 5 minutes, during the homogenization the W1/O 
mixture was poured into the W2 phase. The mixture was then stirred overnight to allow 
the DCM to evaporate. After being stirred overnight the solution was centrifuged down to 
remove the water phases and to rinse the microspheres. The collected microspheres were 
then frozen and lyophilized for 48 hours. The lyophilized microspheres were then 
weighed and the loading was determined.  
 
The loading of the vancomycin or tranexamic acid encapsulated PLGA microspheres was 
determined by dissolving 30 mg of microspheres in 3 mL of DCM for 2 hours. Once the 
PLGA was dissolved 10 mL of PBS was added to the mixture and vortexed for 1 minute. 
Then the mixture was centrifuge for 5 minutes at 1500 RPMs to separate the liquid and 
oil phase. After centrifugation for the vancomycin loaded microspheres, 300 µL was 
pipetted from the liquid phase in a well plate, which was used to measure UV absorbance 
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on a UV plate reader. The samples were measured at 280 nm, and the absorbance values 
measured were compared to a standard curve for vancomycin. For the tranexamic acid 
microspheres 2 mL of the liquid phase were pipetted into a 6 mL glass vial, then 2 mL of 
a ninhydrin solution (0.2% in methanol) was added to the mixture and vortexed. Then the 
samples were heated in a convection oven at 85 °C for 40 minutes. After the 40 minutes, 
the samples were cooled to room temperature. Once cooled, the samples were measured 
for the visible light absorbance at 571 nm. A working standard was prepared with the 
samples to calculate the loading of tranexamic acid.   
3.2. Gelatin microspheres 
 
Gelatin microspheres were prepared using an adapted single-emulsion process [50]. Type 
A gelatin powder (bloom number of 225-325) derived from porcine skin (Sigma Aldrich; 
St. Louis, MO) was dissolved in deionized water at 10% (wt/vol). The gelatin was then 
added to 40 °C olive oil that was being homogenized at 4000 RPMs for 10 minutes. Once 
complete the solution was moved to a stabilized 10 °C water bath for 30 minutes while 
being stirred, then a 25% volume of acetone was added and stirred for 60 minutes. The 
mixture was centrifuged to remove the oil phase and the collected gelatin microspheres 
were washed with cold acetone (4 °C) three times to remove any remaining oil phase. 
The resulting microspheres were then crosslinked for 12 hours with a 20 mM 
glutaraldehyde solution. After 12 hours the crosslinked microspheres were washed with 
deionized water and suspended in 50 mM glycine for 2 hours. The solution was 
suspended in glycine to inactivate remaining glutaraldehyde. The resulting microspheres 
were then washed in acetone and lyophilized for 24 hours.   
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Freeze-dried microspheres were loaded with vancomycin (150 mg/ml) or tranexamic acid 
(75 mg/ml) by absorbing 800 µL for every 200 mg of microspheres. The microspheres 
were stored at room temperature for 3 hours and then freeze dried for 24 hours. Loaded, 
dried microspheres were then ground with mortar and pestle and sieved to ensure 
particles were below 150 µm in diameter.  
 
3.3.  Drug analysis 
 
3.3.1. Vancomycin 
 
Vancomycin concentrations were determined by placing 300 µl of the desired sample in a 
UV-grade 96 well plate (UV Star, VWR Scientific) and measuring absorbance at 280 nm 
using a Biotek Powerwave HT plate reader. Sample absorbances were compared against 
vancomycin standards. 
 
3.3.2. Tranexamic Acid 
 
To analyze the tranexamic acid content 2 mL of the desired TXA solution were pipetted 
into a 6 mL glass vial, then 2 mL of a ninhydrin solution (0.2% in methanol) was added 
to the mixture and vortexed. Then the samples were heated in a convection oven at 85 °C 
for 40 minutes. After the 40 minutes the samples were cooled to room temperature. Once 
cooled, the samples were measure for the visible light absorbance at 571 nm. A working 
standard was prepared with the samples to calculate the concentration of TXA in the 
desired solution.  
 
3.4. Tranexamic acid spray solution 
 
The spray solution was prepared by dissolving the tranexamic acid in PBS with a pH of 
7.4 or a 1% carboxymethyl cellulose (CMC) (Sigma Aldrich; St. Louis, MO) solution at 
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30 mg per 1 ml of liquid. The CMC solution was made by using high viscosity 
carboxymethylcellulose sodium salt powder and deionized water. The 1% CMC solution 
was shaken at 40°C until all the powder was dissolved.  
 
3.5. Release studies 
 
The release of vancomycin from PLGA was studied by immersing loaded PLGA 
microspheres in PBS for an extended period. For the vancomycin release, 90 mg of 
loaded microspheres were placed into a laboratory tube with 6 mL of PBS. The samples 
were shaken horizontally at 86 RPMs at a constant temperature of 37 °C. The samples 
were centrifuged down and supernatants were collected every day for the first 3 days and 
every 3 days after that, for 42 days. The vancomycin concentration was determined by 
using UV absorbance at 280 nm. 
 
To study the release of vancomycin from gelatin microspheres or the release of 
tranexamic acid from PBS or 1% CMC, samples were placed in dialysis tubing 
(Spectrum Laboratories). To test the release of vancomycin from gelatin, dialysis tubing 
(8000 Da cutoff) was loaded with 75 mg of loaded gelatin microspheres and 1.5 ml of 
PBS. To study the release of tranexamic acid from PBS or 1% CMC, dialysis tubing 
(1000 Da cutoff) was loaded with 1.5 ml of loaded PBS or 1% CMC solution (30 mg/ml). 
The concentration of 30 mg/ml was chosen based on literature where the saline 
concentration of tranexamic acid was 3 g per 100 ml [51]. The dialysis tubing was closed 
with weighted clips on each end. The samples were then placed in 40 ml of PBS shaking 
at 86 RPM at 37°C. Supernatants were collected every 2 hours for the first 12 hours, and 
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then everyday consecutively for 10 days. The media was changed and refreshed for each 
supernatant collection.  
 
3.6. Spray gun 
 
The water based spray bottle that was used for this research was purchased at Sam’s Club 
and was used to deliver the microsphere solution to a target area. The spray gun was 
modified in several different ways. First the bottle connection was modified to fit a 50 ml 
centrifuge tube. This was modified by drilling a hole into the center of a tube lid and hot 
gluing the lid to the existing spray bottle connection. The intake tubing was then fed 
through the hole in the lid, to allow for fluid intake. This was done to allow a standard 50 
ml centrifuge tube to be directly screwed onto the spray nozzle. Secondly, the stock 
intake tubing was replaced with a different tubing that had a smaller interior diameter. 
The stock tubing interior diameter was approximately 4.5 mm and the replacement tubing 
had an approximate interior diameter of 1.58 mm. The tubing was modified to allow for a 
smaller volume of flow which allowed more fluid to be sprayed due to the nozzle being 
pressure based.  
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Figure 3.1: Spray gun with 50 ml tube. 
 
Figure 3.2: Modified tubing and 50 ml tube connection. 
3.7. Spray gun experiments 
 
3.7.1. Fluid medium 
 
The spray solution was comprised of two components, the fluid medium and the 
particles. The fluid medium can either be CMC or PBS (pH 7.4). The percentage of CMC 
tested was between 0.25% and 3%. A test was run to determine if the fluid medium could 
50 ml Tube with 
fluid medium 
Spray Trigger 
Spray Nozzle 
50 ml Tube Connection 
Modified tubing 
hole 
Modified 
Tubing 
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be sprayed or not. The particles were 20 mM crosslinked gelatin microspheres or 75:25 
PLGA microspheres. The particles were immersed into the fluid medium at 50 mg/ml. 
3.7.2. Volume per spray 
 
The volume of fluid per spray was measured using PBS and 1% CMC. The nozzle of the 
spray gun was placed into the opening of a graduated cylinder and the trigger was pulled 
for a set number of sprays. The fluid sprayed was then measured using the graduated 
cylinder and recorded. 
3.7.3. Area coverage  
 
The area coverage of the spray system was tested by mounting the spray gun into a tube 
holder on a ring stand. The center of the nozzle was placed 8.5 cm above the test surface 
and at angle of 45°. These parameters were chosen based on consultation with Dr. Todd 
Milbrandt (Department of Orthopedic Surgery, Mayo Clinic) and approximate 
measurements based on possible use in surgery. The test area was a hydrophobic white 
board to allow for the greatest contrast between particles and spray solution. The spray 
gun was loaded with stained PLGA or gelatin microspheres spray solution and primed 
before testing. The system was then sprayed 5 times with pictures taken for area coverage 
analysis after each spray. The spray set up is shown in Figure 3.4 and Figure 3.5 below.  
 
Federal food, drug and cosmetic (FD&C) blue #1 food dye was encapsulated in PLGA 
microspheres to achieve a greater amount of contrast to image and analyze the area 
coverage of the spray patterns. The brilliant blue food dye was encapsulated using double 
emulsion. It was loaded at 2 ml per 1 gram of PLGA. After microsphere formation the 
particles were washed 3 times using a vortex and centrifuge to remove any loose FD&C 
blue #1.  
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One gram of gelatin microspheres was stained with a Bicinchoninic Acid Assay (BCA 
assay) (Pierce; Rockford, Illinois). Using an adaptation of the manufacturer’s protocol, 
100 µL of reagent B were mixed with 5 mL of reagent A and then added drop-wise to the 
gelatin microspheres. The staining resulted in the microspheres being stained purple from 
the BCA assay.  
 
To dye PBS, 0.25% CMC, 0.50% CMC, 0.75% CMC and 1% CMC blue, 250 µl of 
FD&C blue #1 was substituted for 250 µl of PBS or DIH2O. The mixtures were then 
heated at 60°C overnight to allow the mixture to go into solution.  
 
To analyze the spray area coverage images several different steps were taken. First the 
images were enhanced to increase the amount of contrast between the spray solution and 
the background. Windows Live Photo Gallery was first used to automatically enhance the 
exposure and contrast of the images to lighten up the spray patterns. The enhanced photos 
were then opened in GNU Image Manipulation Program (GIMP) to crop the images and 
threshold them. Each image had a different level of threshold due to the subtle changes in 
background lighting, each image was threshold to match the original image but in black 
and white. Once each image was processed in GIMP they were used in ImageJ to 
measure the area coverage. In imageJ a scale was set using a scale bar from the original 
images and then the area coverage was analyzed using Analyze particles. Analyze 
particles has several different parameters to adjust. The size was left from zero to infinity 
to account for possible liquid pooling on the hydrophobic surface. Circularity, which is 
the roundness of the particles was left from zero to one to account for irregular shapes. 
The bare outlines setting was chosen to show what was measured. The particles on the 
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edges were not excluded. Analyze particle works by scanning across the image and once 
it encounters a particle it outlines it and then measures the perimeter and area of the 
particle using pixels. The area is converted from pixels to centimeters by using the preset 
scale. Analyze particles measures the total area that particles occupy in the image 
producing the area coverage per spray. A diagram of the image analysis is shown in 
Figure 3.6 below.  
 
 
Figure 3.3: Area coverage spray testing set up post spray (side view). 
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Figure 3.4: Area coverage spray testing set up post spray (bird's eye view). 
 
 
Figure 3.5: Image Analysis Diagram. 
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3.7.4. Mass of microspheres per spray  
 
The mass of particles per spray was tested for both gelatin and PLGA microspheres. The 
empty mass of 15 mL centrifuge tubes was recorded and the spray gun was loaded with 
either gelatin or PLGA particles at 50 mg/ml in PBS (pH 7.4). Then particles were 
sprayed into the empty tubes for 1 through 5 sprays. The tubes were then frozen, 
lyophilized for 48 hours, and the final mass recorded. The mass of microspheres was 
calculated by subtracting the final mass from the initial mass of the tubes.  
 
3.8. Drip test 
 
The viscosity of PBS, 0.25%, 0.50%, 0.75%, 1%, 2% and 3% CMC was tested. A grid 
was drawn onto a hydrophobic white board to allow for easier image capture with a 
starting dot at the same vertical distance spaced 5 cm horizontally. To test the viscosity of 
the different fluids, 150 µl of each was pipetted onto a separate starting dot. The board 
was then raised to an incline of 30 degrees and held there for 10 minutes. Pictures were 
taken every 2 minutes to document the distance traveled by each fluid. The pictures were 
then analyzed in ImageJ to measure how far each fluid traveled at that time point. In 
ImageJ the scale was set for each picture based on the grid in the pictures then using the 
measure tool the distance of each drip was determined and recorded. The set up for the 
drip test is shown in Figure 3.7 below. 
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Figure 3.6: Representation of Drip Test Set Up. 
 
3.9. Statistics 
 
A fifth order polynomial and two-way analysis of variance (ANOVA) were run using 
Prism GraphPad to statistically analyze the results. Turkey’s and Bonferonni’s test was 
used for the two-way ANOVA. Extra sum-of-the-squares F test was used for the fifth 
order polynomial which determines statistical analysis by fitting the data with a fifth 
order polynomial and determining if the same polynomial curve fits each data set equally. 
Statistical significance was determined at p values less than 0.05.  
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 RESULTS 
 
4.1. Release studies and loadings 
 
4.1.1. Vancomycin encapsulated PLGA microspheres 
 
The release profile of vancomycin from 75:25 PLGA is shown below in Figure 4.1 part 
A. The vancomycin was loaded in at 5%.  There was a high initial burst of vancomycin 
from the microspheres seen in the first 4 days which was followed by a gradual decrease 
in the release of vancomycin. The vancomycin was released for 42 days while staying 
above 6. The cumulative release of vancomycin is shown in Figure 4.1 part B. 
Approximately 5.25 mg of vancomycin were released during the 42 days which was 
69.7% of the total drug loaded.  
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Figure 4.1: (A) Instantaneous and (B) cumulative profiles showing release of vancomycin 
from 75:25 PLGA. Data are mean ± standard deviation (n = 3). The error bars are shown 
on Figure 4.1 part B but are hidden by the data points. The standard deviation ranged as 
high as ± 89 µg and low as ± 7 µg.  
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4.1.2. Vancomycin loaded in 20 mM crosslinked gelatin microspheres 
 
 
The release profile of vancomycin adsorbed and absorbed onto 20 mM crosslinked is 
shown in Figure 4.2 part A. There was a linear release of vancomycin for 48 hours with a 
gradual decrease in the release after 2 days until ending at day 7. The cumulative release 
of vancomycin from gelatin can be found in Figure 4.2 part B. The total amount of 
vancomycin released was approximately 20 mg.  
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Figure 4.2: (A) Instantaneous and (B) cumulative profiles showing release of vancomycin 
from 20mM crosslinked gelatin. Data are mean ± standard deviation (n = 3). 
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4.1.3. Tranexamic acid loading in PLGA 
 
In 75:25 PLGA a loading of 0.62% was achieved which had a release length of 1 day (not 
shown).  
4.1.4. Tranexamic acid release from gelatin microspheres 
 
The release profile for tranexamic acid from 20 mM crosslinked gelatin in PBS and 1% 
CMC is shown in Figure 4.3 part A. Both formulations had an initial burst of tranexamic 
acid and the release decreased until concluding at 12 hours. A fifth order polynomial was 
run to determine the statistical difference between the release of tranexamic acid from 
gelatin in PBS and CMC. The statistical analysis found that there was no significant 
difference between the data. The cumulative release of tranexamic acid from gelatin in 
PBS and 1% CMC is shown in Figure 4.3 part B. Approximately 10 and 16 mg of TXA 
was released for PBS and CMC.  
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Figure 4.3: (A) Instantaneous and (B) cumulative profiles showing release of tranexamic 
acid from 20mM crosslinked gelatin in PBS and 1% CMC. Data are mean ± standard 
deviation (n = 3). 
4.1.5. Tranexamic release profile from PBS and 1% CMC 
 
The release profile of tranexamic acid from PBS and 1% CMC is shown in Figure 4.4 
part A. There was an initial burst of tranexamic acid in the first hour of the release and it 
continues to slowly release until the PBS and CMC finished releasing the tranexamic acid 
in 7 hours. A fifth order polynomial was run to analyze the statistical difference between 
the release of TXA from PBS and CMC. No statistical difference was found. The 
cumulative mass release is shown in Figure 4.4 part B. Approximately 25 mg of 
tranexamic acid was released in PBS, and 33 mg of tranexamic acid was released in 
CMC.  
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Figure 4.4: (A) Instantaneous and (B) cumulative profiles showing release of tranexamic 
acid from 20mM crosslinked gelatin in PBS and 1% CMC. Data are mean ± standard 
deviation (n = 3). 
4.2. Spray solution 
The spray solution was tested with several different types of fluid media based on 
increasing percentages of CMC. All the fluid mediums were able to be sprayed when set 
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on a mist setting except for 2% and 3% CMC. The results of the test are shown in Table 
4.1. 
 
Table 4.1: Spray Solution Test. 
Fluid Medium PBS 0.25% 
CMC 
0.50% 
CMC 
0.75% 
CMC 
1% 
CMC 
2% 
CMC 
3% 
CMC 
Able to be Sprayed:  Yes Yes Yes Yes Yes No No 
 
4.3. Volume per spray 
 
The volume per spray was very consistent, the spray gun sprayed about 0.9 ml of fluid 
per spray regardless on the number of trigger pulls. No statistical difference was found 
between the two. The results for the volume per spray are shown in Figure 4.5.  
 
 
 
Figure 4.5: Volume per spray for the spray system. Data are mean ± standard deviation (n 
= 3). 
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4.4. Area coverage 
 
The area coverage for 7 different fluid mediums are shown in Figure 4.6. As the number 
of sprays increased so did the area coverage regardless of the spray medium. PBS, 0.25% 
CMC, Gelatin and PLGA microspheres have the greatest area coverage when suspended 
in PBS. Images of the 1st and 5th for area coverage of the 7 different fluid mediums is 
shown in Figure 4.7. The individual images were the ones used in ImageJ to measure the 
area coverage. For each fluid medium the area coverage increases between 1 spray and 5 
sprays as more fluid medium is sprayed onto a target region which can be seen in Figure 
4.7. Two way ANOVA showed statistically significant differences with respect to fluid 
medium, spray number, and the interaction between the fluid medium and spray number 
(p < 0.0001). 
 
 
Figure 4.6: Area coverage for different numbers of sprays. Data are mean ± standard 
deviation (n = 3)
 
 
 
 
 
 
Figure 4.7: First and fifth sprays for area coverage analysis. 
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4.5. Mass of microspheres per spray  
 
The mass of microspheres delivered for 1 through 5 sprays is shown in Figure 4.8 and 
Figure 4.9. Approximately 45 mg of microspheres should be sprayed for each pull of the 
trigger. This was determined from the loading of the microspheres and volume of fluid 
per spray. As the number of sprays increased, the mass of microspheres sprayed 
increased as well. No statistical difference was found between gelatin and PLGA 
microspheres. After running a two way ANOVA it was found that the interaction 
between the type of polymer sprayed and the number of sprays was statistically 
significant (P = 0.011). Two-way ANOVA also showed no statistical significance 
between PLGA and gelatin microspheres for the mass of microspheres sprayed.  
 
 
Figure 4.8: Cumulative mass of microspheres per spray for gelatin and PLGA 
microspheres. Data are mean ± standard deviation (n = 3). 
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Figure 4.9: Mass of microspheres per spray for 1 through 5 sprays for gelatin and PLGA 
microspheres. Data are mean ± standard deviation (n = 3). 
4.6. Drip Test 
 
For each of the fluid mediums, the distance traveled increased with time. The results from 
the drip test are shown Figure 4.9 and the correlating drip rates are shown in Table 4.2. 
PBS reached the maximum distance that could be measured (50 cm) in under 2 minutes 
which is why it remained constant for the remainder of the test. PBS has the greatest drip 
rate of any fluid medium tested at 25.0 cm/min. The second fastest drip rate was 0.25% 
CMC at 4.33 cm/min. As the percentage of CMC increased, the drip rate decreased. Two-
way ANOVA showed statistical significance for the fluid medium, time and the 
interaction between fluid medium and time (P < 0.0001). Significant differences were 
found for PBS, 0.25% CMC and 0.50% CMC when compared against all other fluid 
media at all time points. No significant difference was found between 0.75% CMC and 
1% CMC. No significant differences were found between 1%, 2% and 3% CMC.  
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Figure 4.10: Drip test for different fluid mediums. Data are mean ± standard deviation (n 
= 3). 
Table 4.2: Drip rate for different fluid mediums. 
Fluid Medium Mean Drip Rate (cm/min) 
PBS 25.0 
0.25% CMC 4.33 
0.50% CMC 1.71 
0.75% CMC 0.83 
1.0% CMC 0.47 
2.0% CMC 0.17 
3.0% CMC 0.09 
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 DISCUSSION 
 
Blood loss and the potential for infection remain significant complications of spinal 
fusion. A sprayable system was developed for localized delivery of antibacterial and anti-
fibrinolytic agents to a target area. The antibacterial agent could be used to prevent and 
treat infection in the surgical site. The antifibrinolytic agent could prevent and treat blood 
loss after surgery and therefore reduce the risks. The spray system was created to 
improve upon the current techniques.  
 
For prolonged release of vancomycin, the antibiotic was encapsulated into degradable 
PLGA microspheres.  The concentration of vancomycin remained above 2 µg/ml for the 
42 days of the PLGA release study. This was important because it was greater than the 
minimum inhibitory concentration (MIC) of S. aureus [52]. The lowest concentration 
released was on day 42, which was 6.2 mg/ml. The 42 days of antibiotic release was 
important due to the current methods used to treat a spinal fusion surgical site infection. 
Current methods used to treat an infection require antibiotics intravenously for a mean 
time of 6 weeks. Oral antibiotics may be needed for several months after intravenous 
antibiotics and in some cases multiple debridements of the surgical site to fully remove 
the infection [7, 9, 24, 25]. Multiple debridement procedures can result in soft tissue 
damage and can require additional surgeries. Debridement for spinal fusion surgery 
involving instrumentation can be difficult or impossible to perform. If performed, there is 
an increased risk for pseudoarthritis [9, 24, 25]. The controlled release of the antibiotic 
for 6 weeks may allow the PLGA microspheres to be used to treat a postoperative spinal 
fusion infection.  
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Vancomycin released from gelatin microspheres had a sustained release of 7 days with a 
delay in the initial burst. The initial delay in the burst was hypothesized to be due to 
electrostatic interactions between the vancomycin and gelatin microspheres [53]. The 7 
day mark was important due to the need to prevent infection after spinal fusion surgery. 
The release of vancomycin stayed well above the MIC for S. aureus until the 7 day mark. 
The current technique used to prevent infections (1 gram of vancomycin powder spread 
on the wound) provides 3 days of detectable vancomycin levels in the wound drain and 
successfully prevents infection [8, 22]. Infection rates were reduced from as high as 8.5% 
to 0% after application of the vancomycin powder in the surgical site [7, 54]. The 
controlled release of vancomycin for 7 days may allow the gelatin microspheres to 
prevent surgical site infection. Therefore, it could be used as an alternative prevention 
method.  
 
PLGA and gelatin microspheres were each tested in a variety of ways to determine 
whether they could be used in the spray system. Area coverage was an important test 
because if the microspheres were being distributed onto the target region it means the 
encapsulated drugs are also being distributed over the target region. A large area 
coverage was also important as well. A larger area coverage would indicate that the 
microspheres are being distributed over a greater area of the wound site. This would 
allow the vancomycin that was encapsulated to work over a greater area and prevent/treat 
infection over a greater region. The average surgical wound size for a single spinal fusion 
is approximately 10 cm wide by 12 to 15 cm long [55]. For multiple spinal fusion surgery 
the wound size is approximately 10 cm by 28 to 30 cm long, based on consultation with 
Dr. Todd Milbrandt (Department of Orthopedic Surgery, Mayo Clinic). For each case this 
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results in the total area of the wound site to be between 120 to 150 cm2 for a single fusion 
and between 280 to 300 cm2 for multiple fusions. PLGA and gelatin microspheres had 
area coverages of approximately 90 and 120 cm2 at five sprays, respectively. The area 
coverage test was static, meaning the spray system was not moved around, which resulted 
in a large amount of pooling of the fluid medium. It is hypothesized that if the spray 
system was dynamic the area coverage would increase. Nonetheless, the area coverage 
testing showed that the PLGA and gelatin microspheres could be used to distributed 
microspheres encapsulating vancomycin onto the entire surface of the wound site with 
more sprays.  
 
The next test performed with the PLGA and gelatin microspheres was the mass of 
microspheres per spray. This was an important test because it was used to verify that 
microspheres were in fact being sprayed and what mass of microspheres were 
approximately being sprayed for each pull of the trigger. This test was also used to 
validate that the area coverage measured was from the microspheres and the fluid 
medium not just the fluid medium solely. It was expected for no statistical difference to 
be found between PLGA and gelatin microspheres due to equal particle density 
(mass/volume). There was some error in the test which resulted from the need to prime 
the spray gun before the first spray. Priming the spray gun means that they was no spray 
solution in the intake tubing during the first pull of the trigger, therefore the trigger must 
be pulled several times to start the uptake of the spray solution. This can skew results 
because the first few sprays may only have a partial or lack of spray solution expelled. 
This problem would be addressed in the development of the device for the market. The 
spray system delivered approximately 40 to 45 mg of PLGA or gelatin microspheres per 
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spray when properly primed. Knowing the loading of vancomycin in the microspheres 
and the mass of microspheres sprayed could be used to calculate the appropriate dosage 
of vancomycin for the patient. At this time the current dose of vancomycin most 
commonly used is 1 gram of vancomycin powder spread into the surgical site [8, 17, 54]. 
Most of the vancomycin is flushed out the wound very quickly through the wound 
drainage [22]. On the day of the surgery and one day after, approximately 1450 µg/ml 
and 450 µg/ml, respectively, of vancomycin were found in the wound drainage [22]. 
Therefore, the use of 1 gram of vancomycin is very wasteful because most of the 
vancomycin in quickly flushed out of the wound. To properly prevent infection the 
concentration of vancomycin must remain higher than the MIC of the most common 
organism S. aureus. The MIC of S. aureus is 2 µg/ml and the average volume of fluid 
loss during spinal fusion is between 750 and 1500 ml [56]. To ensure that the infection is 
being prevented we can aim for a concentration of 10 µg/ml of vancomycin. This 
concentration was chosen to account for any possible loss of antibiotic due to wound 
drainage. To achieve a concentration of 10 µg/ml we would need to spray 15 mg of 
antibiotic into the wound, and if the microspheres are loaded with vancomycin at 5% we 
would need to start with 300 mg of antibiotic. Using this method to prevent infection you 
can reduce the total amount of antibiotic needed by 700 mg and you can reduce the 
amount entering the wound site by 985 mg.  
 
The size of the microspheres sprayed could play a large role in several different aspects 
of the spray system and lifespan of the particles. If the microspheres sprayed were too 
large they could clog the spray system which would prevent the system from working 
properly. Depending on the size of the microspheres they could be phagocytized by 
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macrophages which are present during wound healing. It has been shown that polymeric 
particles can be phagocytized if their diameter is between 1 and 9 µm [57]. The PLGA 
microspheres used in this study were found to be 40 µm or greater in diameter. The 
gelatin microspheres were sieved with a maximum diameter of 150 µm, but they will 
swell in the presence of water to increase in size. Therefore, phagocytosis of the 
microspheres used in a wound is unlikely due to the size of the particles used. Frustrated 
phagocytosis is likely to occur, however. This occurs when the substrate is too larger to 
be phagocytized by macrophages. In this case, the macrophages will fuse together to 
form a foreign body giant cell and start to release superoxides and free radicals, which 
can damage the microspheres as well as surrounding tissues [58]. 
 
At this time no other spray system is being used to treat/prevent surgical site infections in 
spinal fusions. There are several different systems that can be used to deliver antibiotics. 
These systems can be injections, inhalable, bone cements or topical sprays. Injections can 
have antibiotics encapsulated in particles to be delivered to a localized site for drug 
delivery [44]. Inhalable drugs such as steroids are often used to treat lung diseases [59]. 
Another controlled release system that has been found was bone cement with antibiotics 
mixed directly into poly (methyl methacrylate) which is not relevant for this surgery [60]. 
Lastly spray systems are being used to treat burn wounds. Currently an aerosol haruan 
spray is being used on burns. It has been found that it reduces infection and promotes 
rapid healing. The haruan is in a saline solution and directly sprayed onto the burn site 
[61].  
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Several different experiments were run to test the spray system and the possible fluid 
media for the spray system. One experiment run was a drip test on seven different fluid 
media. The drip test was run to determine the viscosity of the fluid media. As stated in 
the results as the percentage of CMC increased the viscosity increased as well. In a 
surgical site there is major blood loss and poor fluid retention due to the high volume of 
blood loss. The average blood loss in spinal fusion surgery ranges between 750 and 1500 
ml [5, 56]. There have been some reported cases of blood loss as high as 2839 ml in a 
spinal fusion surgery [5]. The hypothesis of the drip test was that if a higher viscosity 
fluid was sprayed onto the wound it would adhere to the surgical wound more and would 
not be lost as quickly. If the fluid media had a higher viscosity it would help prevent or 
reduce the time it takes for the fluid sprayed to leave the surgical site. This would allow 
any of the drugs sprayed to stay in the wound longer and provide them with more time to 
function.  
 
The sprayability experiment tested seven different fluid media in increasing viscosity. 
The only two fluid media that could not be sprayed were 2.0% CMC and 3.0% CMC. 
The system became clogged due to the viscosity of the fluid medium. When the system 
became clogged, the trigger was no longer able to be pressed. This test was used to 
determine which fluid media to test area coverage and the drip test on.  
 
The next test was run on the spray system and the fluid media. The test run was volume 
per spray. This was an important experiment because it proved that the volume per spray 
is roughly 0.9 ml per spray for either fluid media. To calculate the dosage for the anti-
fibrinolytic agent the user only needs the loading of TXA in the fluid media and the 
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volume per spray. Therefore, if the loading of the tranexamic acid is 30 mg/ml and the 
user sprays 5 times the total amount of tranexamic acid sprayed is 135 mg.  
 
The last experiment run was the area coverage testing of the different fluid media. Much 
like the area coverage testing of the microspheres, this experiment was run to verify that 
the different fluid mediums were being distributed onto the target region. The experiment 
was also run to determine the trend of area coverage as the percentage of CMC increases. 
Due to no significant difference being found between PBS and 0.25% CMC, the two 
fluids could be used interchangeably without compromising area coverage. The 0.25% 
CMC could be used to distribute the microspheres or anti-fibrinolytic to a large region of 
the target area. The 0.25% CMC would also provide increased viscosity without a 
reduction in area coverage when compared to PBS. All higher percentages of CMC had 
increased viscosity but with a reduction in area coverage. When sprayed, PBS and 0.25% 
CMC came out in a mist, while 0.5%, 0.75% and 1% CMC came out in a stream on the 
same setting. The fluid media was too viscous to spray in a mist.  
 
Tranexamic acid was successfully loaded into 75:25 PLGA with a loading of 0.6%. 
When a release study was performed on the 75:25 PLGA the tranexamic acid was 
released in 24 hours. This release length is favorable for tranexamic acid because 
postoperatively it can be administered between 6 and 12 hours [5, 12]. The release length 
was unfavorable for PLGA due to the degradation length of 75:25 PLGA. The drug 
would be released in 24 hours and the PLGA would remain in the wound site for several 
more weeks, which could possibly cause inflammation [31, 62].  
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Tranexamic acid was adsorbed and absorbed onto gelatin microspheres after trying 
PLGA microspheres. A release study was performed to determine the duration of 
tranexamic acid release. The release profile achieved had 12 hours of release in PBS and 
1% CMC. The fluid medium did not change the release of tranexamic acid. This was 
favorable because a higher viscosity solution could be used without altering the release 
profile of the drug. Once again though the release length was typical for tranexamic acid 
but unfavorable for gelatin microspheres. The degradation length of gelatin was much 
longer which could cause inflammation in the wound site [63]. 
 
Based on the normal clinical dosing length of tranexamic acid a release study was run on 
tranexamic acid dissolved into PBS and 1% CMC. No polymer was used. The resulting 
release profile was 6 hours of tranexamic release from both the 1% CMC and PBS. This 
indicates that the release length of tranexamic acid was not dependent on the fluid 
medium. The release profile was favorable for tranexamic acid because long term dosing 
is not required due to the uses of tranexamic acid [6, 15, 16, 30]. It has been shown that 
tranexamic acid administered up to 2 to 6 hours after surgery will reduce blood loss for 
24 hours [5, 13, 15].    
 
Antibacterial sprays are not a novel concept. An antibiotic topical spray was tested for 
possible use in combat wounds during the Vietnam War. The spray system consisted of 
100 mg of oxytetracycline hydrochloride, isopropyl myristate and a propellant. The 10 cc 
solution was sprayed onto the wound to prevent infection. It was shown that the infection 
rate was reduced when using the spray but debridement was still necessary to prevent 
infection, the spray system only prevented the onset of infection for a few days [64]. 
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Another spray system was used during the 1980s to determine whether an antibacterial 
spray could prevent infection after an appendectomy. The spray system was a povidone-
iodine dry powder aerosol spray. It was sprayed into the surgical wound and again after 
the closing of the wound to ensure there was a good coating of powder. No significant 
results were found using the povidone-iodine spray. The spray did not prevent or reduce 
infection rates [65].  There are also a large number of antibacterial spray systems on the 
market today. Some examples of these antibacterial sprays are Dermoplast, Bactine 
sprays and Neosporin sprays. These can all be bought at any pharmacy without a 
prescription. 
 
Currently no spray systems found utilize the controlled release of antibiotics. The 
microsphere spray system was able to utilize the controlled release of antibiotics to 
prevent or treat infection. The microsphere spray system also had the combined release of 
tranexamic acid release from the fluid media. These combined features make the 
microsphere spray system a novel and practical solution to improving spinal fusion 
surgery recovery. 
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 CONCLUSION 
 
The goal of this research was to develop a better method and system to prevent and treat 
blood loss and infection in spinal fusion surgery. The spray system for wound coverage 
demonstrated delivery of antibacterial and antifibrinolytic agents to a target area through 
the area coverage and mass of microspheres per spray. The area coverage confirmed that 
particles would be distributed to a large area of the surgical site maximizing the potential 
of the drugs encapsulated. The use of CMC allowed the spray solution to have increased 
viscosity to reduce the loss of drugs. The release studies showed that vancomycin can be 
released for 42 or 7 days, depending on the use of PLGA or gelatin microspheres, 
respectively. The tranexamic acid was shown to be released from PBS or CMC by 
diffusion over 6 hours. The different drug solutions can be used to treat or prevent 
infection and blood loss in spinal fusion surgery. Animal testing is required to fully 
support that this system is an improvement upon the current techniques. Future work in 
the project could be addressing biofilms and tailoring the spray system for a wider range 
of applications.  
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